Lockhart M, Ali E, Mustafa M, Tormey W, Sreenan S, Saaed A, McDermott J H
Academic Department of Endocrinology and Pathology, Connolly Hospital Blanchardstown/RCSI, Lucan, Ireland.
Ophthalmological Surgery Department, Hermitage Medical Clinic, Lucan, Ireland.
Endocrinol Diabetes Metab Case Rep. 2023 May 22;2023(2). doi: 10.1530/EDM-22-0348. Print 2023 May 1.
A patient treated with intramuscular testosterone replacement therapy for primary hypogonadism developed blurred vision shortly after receiving his testosterone injection. The symptom resolved over subsequent weeks and recurred after his next injection. A diagnosis of central serous chorioretinopathy (CSR) was confirmed following ophthalmology review. A decision was made to change the patient's testosterone regime from this 12-weekly intramuscular injection to a daily topical testosterone gel, given the possibility that peak blood levels of testosterone following intramuscular injection were causing his ocular complaint. His CSR did not recur after this change in treatment. CSR secondary to testosterone therapy is a rare finding but has been reported previously in the literature.
Blurred vision in patients treated with testosterone replacement therapy (TRT) should prompt an ophthalmology review. The potential for reduced risk of central serous chorioretinopathy (CSR) with daily transdermal testosterone remains a matter of conjecture. CSR is a rare potential side effect of TRT.
一名接受肌肉注射睾酮替代疗法治疗原发性性腺功能减退的患者，在接受睾酮注射后不久出现视力模糊。症状在随后几周内缓解，并在下次注射后复发。眼科检查后确诊为中心性浆液性脉络膜视网膜病变（CSR）。鉴于肌肉注射睾酮后血液中睾酮峰值可能导致其眼部不适，决定将患者的睾酮治疗方案从每12周一次的肌肉注射改为每日外用睾酮凝胶。治疗方案改变后，他的CSR未再复发。睾酮治疗继发的CSR是一种罕见的发现，但此前文献中已有报道。
接受睾酮替代疗法（TRT）的患者出现视力模糊应促使进行眼科检查。每日经皮使用睾酮降低中心性浆液性脉络膜视网膜病变（CSR）风险的可能性仍存在推测。CSR是TRT一种罕见的潜在副作用。
